Hematologic Malignancy
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
CI-CAN-00006470Explore in graph →
Hematologic7 active trials
- NCIt
- C41233
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006470Explore in graph →
Clinical trials
28 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04896112 | A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Lynk Pharmaceuticals Co., LtdINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04283526 | Study of Select Combinations in Adults With Myelofibrosis | withdrawn | Phase 1 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Mar 4, 2021 | clinicaltrials |
| NCT02871323 |
| Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis |
| withdrawn |
| Phase 1 |
| 0 |
| Northwestern UniversityOTHER |
| 1 |
| Aug 20, 2019 |
| clinicaltrials |
| NCT04054245 | PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Jun 18, 2023source: clinicaltrials